MEDIA

Media Inquiries

Investors@OncoSec.com

855-662-6732

Press Releases

VIEW ALL PRESS RELEASES

Video Feed

3D MOA Animation video

✕

OncoSec's VLA 3D MOA Animation

✕

TAVO Demonstration with Dr Algazi

✕

OncoSec at 2020 BIO CEO Panel

✕

Tumor Immunogenicity

✕

IAD Reel

✕

IAD Robert Andtbacka, M.D.

✕

Social Media

Twitter Feed

OncoSec Medical@OncoSec·
1 Mar

#DYK that this month is #TNBCAwarenesMonth? Join us in recognizing #TNBC awareness and learn how we're working to deliver safe and effective cancer treatments for patients: http://bit.ly/3pHwpLt

OncoSec Medical@OncoSec·
26 Feb

Join us in supporting many of the world’s most renowned #melanoma researchers at the International Melanoma Working Group Conference (#IMWG) on February 27th & 28th! Learn more here: http://bit.ly/36eTiPP

Melanoma Research@MelanomaReAlli·
24 Feb

A huge thanks to @OncoSec for supporting the 2021 MRA Annual Scientific Retreat as a Silver Level Sponsor! #Melanoma

OncoSec Medical@OncoSec·
23 Feb

#ICYMI we announced the closing of a previously announced underwritten public offering of common stock. Learn more here: http://bit.ly/3okFSHZ #BiotechNews $ONCS

Featured Articles

Melanoma Research Alliance

From Dermatology to Treatment: Second Opinions, Clinical Trials & becoming Your Own Best Advocate

PharmaVoice

Women of the Week interview with OncoSec’s Chief Clinical Development Officer, Kellie Malloy Foerter

Annals of Oncology

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients

Clinical Cancer Research

Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.